Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP6V1G2 encodes subunit G2 of the V1 domain of vacuolar H+-ATPase (V-ATPase), a multisubunit ATP-dependent proton pump critical for acidifying intracellular compartments such as lysosomes, endosomes, and synaptic vesicles[1][3][5][6]. The V1 sector, where G2 localizes, is responsible for ATP hydrolysis, which energizes proton translocation via the V0 membrane domain. The G2 isoform is selectively expressed in neurons, where it supports neurotransmitter loading into synaptic vesicles—a key step for synaptic transmission. More broadly, V-ATPase-dependent acidification is crucial for protein processing, immune responses, and receptor-mediated endocytosis. Disruption of V-ATPase function, including mutations or altered expression of ATP6V1G2, has been implicated in neurological dysfunction and potentially in immune system modulation[3][5][6]. Essential details: - Subunit G2 is a ~13 kDa protein forming part of the peripheral stalk that connects V1 and V0 domains, contributing to enzyme structural integrity and regulatory dissociation/association cycles[5]. - In mammals, three genes encode G subunit isoforms (ATP6V1G1, ATP6V1G2, ATP6V1G3), with ATP6V1G2 predominantly neuronal[5]. - Mutations or loss of ATP6V1G2 can impact synaptic physiology and may contribute to neurodevelopmental or degenerative diseases[3][5]. - While the entire V-ATPase complex is a validated therapeutic target (e.g., for osteoporosis, cancer, viral infections), subunit-specific targeting has not been achieved as of the available evidence.
General V-ATPase inhibitors decrease acidification of intracellular vesicles, thus interfering with protein degradation, neurotransmitter loading, or viral entry
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vacuolar proton pump subunit G2 (ATP6V1G2).